News – HollisterStier Allergy

A Message to Our Customers About Coronavirus (COVID-19)

UncategorizedMarch 20, 2020

Jubilant Life Sciences Limited : pro-active, multi-pronged measures to curb the spread of novel Coronavirus (COVID-19)

Industry NewsMarch 17, 2020

Given the recent threat by the novel Coronavirus (COVID-19), Jubilant Life Sciences Limited has taken several proactive measures to curb the spread of the contagious virus among its employees and stakeholders. A company-wide awareness campaign was launched with informative emailers. Internal travel advisories have been issued to all employees and all international and domestic travel…

Details

New Packaging & Labeling

Featured ProductOctober 1, 2019

If you’ve placed an order recently you may have noticed some changes. HollisterStier Allergy is proud to offer the same quality products with an updated look. Our product packaging and labels have been revamped to meet FDA serialization standards.

HollisterStier Allergy Botanist Led Pollen Walks: Where Classroom Meets Nature

Industry NewsSeptember 13, 2019

Did you know our New Fellows Program offers botanist led pollen walks for Allergy Fellows? In late July, Sam Wauford, Eastern Regional Sales Manager and botanist, along with Matthew Brennan, Account Executive for NJ/NY/CT, conducted a pollen walk for eight Allergy Fellows in training from Montifiore Medical Center, Bronx, NY. Finding weeds in the urban…

Details

Venom Immunotherapy Supply Update

Industry NewsMay 7, 2019

One year ago, we announced that our company had become the sole provider of venom immunotherapy products in the U.S.—a position brought about by the departure from the market of the only other supplier. In the ensuing year, we have committed all of our resources to ensuring a long-term, consistent supply of venom products for our customers. We’re pleased to share with you this brief overview of what we’ve been working on, and advances CMS has made with reimbursements.

Details

BeeAware Allergy Relaunches

Press ReleaseJanuary 5, 2019

New Year • New Program For nearly a decade, HollisterStier Allergy’s BeeAware program has helped educate patients and physicians about venom immunotherapy. We are excited to announce the roll-out of our refreshed BeeAware program and the launch of a fresh and updated website. Patient education delivered in a new and improved package The BeeAware program…

Details

Venom Immunotherapy Supplies

Industry NewsMay 16, 2018

Read as letter Read related AAAAI/ACAAI email to members At the end of February 2018, we learned that we will be the only supplier of venom immunotherapy products in North America. In light of this situation, we have evaluated our production capabilities as they relate to our ability to indefinitely supply the entire North American…

Details

Man’s best friend

Featured ProductApril 16, 2018

It may be AP Dog if he’s allergic to his canine companion. According to the U.S. Pet Ownership & Demographics Sourcebook (2012), there is at least one dog living in over 36 percent of US households. That translates to 43,346,000 homes with at least one dog in residence. While only 10 percent1 of people are allergic to them,…

Details

Chris Preti Joins Company as President

Press ReleaseApril 16, 2018

January 22, 2018 – Jubilant Pharma announces the appointment of Chris Preti to the position of President for its allergy company, HollisterStier Allergy. Mr. Preti has over 25 years of progressive pharmaceutical experience. He began his career at GlaxoSmithKline in research and development, developing products for regulatory submission across multiple therapeutic areas. He then joined…

Details

AAAAI | ACAAI Venom Extract Shortage Task Force Report

Industry News, Press ReleaseFebruary 23, 2017

Joint Message Announcing Venom Extract Shortage Task Force Report The AAAAI and ACAAI previously announced a venom extract shortage due to ALK – Abello A/S experiencing a manufacturing delay in regards to its venom products. In response, we formed a task force of experts to generate guidance outlining recommendations for our members which could lead…

Details

WARNING Important Safety Information

See full prescribing information for complete boxed warning.

Intended for use only by licensed health care provider experienced in administering allergenic extracts and trained to provide immediate emergency treatment in the event of a life-threatening reaction. Observe patients for at least 30 minutes following administration. Immunotherapy may not be suitable for patients with medical conditions that reduce their ability to withstand a systemic reaction. Allergenic extracts can cause serious systemic reactions, including anaphylactic shock and in rare cases death, especially in patients who have severe or steroid-dependent asthma, cardiovascular disease, or in patients who use beta blockers. Do not inject intravenously. This product is intended for subcutaneous injection for immunotherapy and percutaneous use for diagnosis. Refer to contraindications, warnings, precautions, adverse reaction and over dosage for more detailed information.

Adverse Reactions

Adverse reactions on our products can be reported by calling 800-495-7437, or by sending us an email. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 800-FDA-1088.

For full prescribing information see our package inserts here

Privacy Policy

Our Privacy Policy has been updated. To give you a better understanding of how we treat your data, please review this Privacy Policy

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Review our use of cookies for more details.